Exploring the role of androgen receptor blockade in increasing the expression of prostate specific membrane antigen (PSMA) and enhancing 68Ga-PSMA-11-PET/CT imaging in patients with metastatic prostate cancer
- Conditions
- Prostate CancerCancer - Prostate
- Registration Number
- ACTRN12619000720112
- Lead Sponsor
- GenesisCare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 40
•Male, aged 18 years or over
•Metastatic prostate cancer with demonstrated resistance to standard ADT
•Eastern Cooperative Oncology Group (ECOG) score 0 or 1 or 2
•Willing and able to comply with all study requirements, including all imaging and pre- and post-study assessments
•estimated glomerular filtration rate (eGFR) greater than or equal to 40 mL/min/1.73 m^2
•Prostate cancer with significant neuroendocrine or sarcomatoid component
•Chemotherapy within previous two months
•External beam radiotherapy within previous two months
•Current use of abiraterone, or use within previous two months
•Known intolerance or hypersensitivity to enzalutamide, or patient in whom enzalutamide is contraindicated
•Known hypersensitivity to CT imaging intravenous contrast agent
•Known hypersensitivity to any isotope of Ga in any chemical form, or any of the PSMA-targeting ligands
•Significant urinary incontinence
•Any mental condition or cognitive impairment that may render the patient unable to adequately understand the requirements, nature and possible consequences of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method